BR112012012025A2 - polipeptídeo imunomodulador derivado da interleucina-2, proteína de fusão, composição farmacêutica e usos do polipeptídeo e da proteína de fusão - Google Patents
polipeptídeo imunomodulador derivado da interleucina-2, proteína de fusão, composição farmacêutica e usos do polipeptídeo e da proteína de fusãoInfo
- Publication number
- BR112012012025A2 BR112012012025A2 BR112012012025A BR112012012025A BR112012012025A2 BR 112012012025 A2 BR112012012025 A2 BR 112012012025A2 BR 112012012025 A BR112012012025 A BR 112012012025A BR 112012012025 A BR112012012025 A BR 112012012025A BR 112012012025 A2 BR112012012025 A2 BR 112012012025A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion protein
- present
- polypeptide
- polypeptides
- interleukin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"polipeptídeo imunomodulador derivado da interleucina-2, proteína de fusão, composiçao farmacêutica e uso do polipeptídeo e da proteína de fusão". a presente invenção se relaciona em geral com polipeptídeos cuja sequência primária tem uma alta homologia com a sequência da interleucina-2 humana (il-2) com algumas mutações pontuais na sequência da il-2 nativa. os polipeptídeos da presente invenção têm um efeito imunomodulador sobre o sistema imune, que é seletivo/preferencial sobre células t reguladoras. a presente invenção também se relaciona com polipeptídeos específicos cuja sequência de aminoácidos é divulgada na presente invenção. em outro aspecto a presente invenção se relaciona com as composições farmacêuticas que compreendem como principio ativo os polipeptídeos divulgados. por último a presente invenção se relaciona com o uso terapêutico dos polipeptídeos e composições farmacêuticas divulgados dado seu efeito modulador do sistema imune sobre patologias como câncer e doenças infecciosas crônicas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2009-0203 | 2009-11-27 | ||
CU20090203A CU23734A1 (es) | 2009-11-27 | 2009-11-27 | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas |
PCT/CU2010/000005 WO2011063770A2 (es) | 2009-11-27 | 2010-11-26 | Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112012012025A2 true BR112012012025A2 (pt) | 2016-05-17 |
BR112012012025B1 BR112012012025B1 (pt) | 2021-05-11 |
BR112012012025B8 BR112012012025B8 (pt) | 2021-05-25 |
Family
ID=43646474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012012025A BR112012012025B8 (pt) | 2009-11-27 | 2010-11-26 | polipeptídeo imunomodulador derivado da interleucina-2, proteína de fusão, composição farmacêutica e usos do polipeptídeo e da proteína de fusão |
Country Status (24)
Country | Link |
---|---|
US (1) | US8759486B2 (pt) |
EP (1) | EP2505206B1 (pt) |
JP (1) | JP5680661B2 (pt) |
KR (1) | KR101484590B1 (pt) |
CN (1) | CN102665754B (pt) |
AR (1) | AR079197A1 (pt) |
AU (1) | AU2010324254B2 (pt) |
BR (1) | BR112012012025B8 (pt) |
CA (1) | CA2781173C (pt) |
CL (1) | CL2012001030A1 (pt) |
CO (1) | CO6501124A2 (pt) |
CU (1) | CU23734A1 (pt) |
EA (1) | EA021867B1 (pt) |
EC (1) | ECSP12011803A (pt) |
ES (1) | ES2643465T3 (pt) |
HK (1) | HK1169961A1 (pt) |
MX (1) | MX2012006077A (pt) |
MY (1) | MY162324A (pt) |
NZ (1) | NZ599792A (pt) |
PE (1) | PE20121636A1 (pt) |
SG (1) | SG181089A1 (pt) |
TN (1) | TN2012000182A1 (pt) |
WO (1) | WO2011063770A2 (pt) |
ZA (1) | ZA201203762B (pt) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112839964A (zh) * | 2018-06-07 | 2021-05-25 | 普泰公司 | 包含融合蛋白的药物组合物及其用途 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
EP3049445A4 (en) | 2013-09-24 | 2017-10-25 | Medicenna Therapeutics, Inc. | Interleukin-2 fusion proteins and uses thereof |
ES2906598T3 (es) | 2014-03-17 | 2022-04-19 | Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch Inst Vertreten Durch Seinen Praeside | Un medicamento para el uso en un método para inducir o extender una respuesta inmunitaria citotóxica celular |
US10150802B2 (en) | 2014-04-24 | 2018-12-11 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
WO2017096262A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
CN110087681A (zh) | 2016-09-28 | 2019-08-02 | 佐马美国有限公司 | 结合白细胞介素-2的抗体和其用途 |
CU24483B1 (es) * | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
CA3067909A1 (en) | 2017-06-19 | 2018-12-27 | Medicenna Therapeutics Inc. | Uses and methods for il-2 superagonists, agonists, and fusions thereof |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
TW202003551A (zh) | 2018-03-28 | 2020-01-16 | 美商必治妥美雅史谷比公司 | 介白素-2/介白素-2受體阿法融合蛋白及其使用方法 |
AU2019246389A1 (en) * | 2018-03-28 | 2020-08-27 | Ascendis Pharma Oncology Division A/S | IL-2 conjugates |
WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
KR20220035333A (ko) | 2019-05-20 | 2022-03-22 | 팬디온 오퍼레이션스, 인코포레이티드 | Madcam 표적 면역관용 |
US11491205B2 (en) | 2020-01-14 | 2022-11-08 | Synthekine, Inc. | Biased IL2 muteins methods and compositions |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
EP4209503A1 (en) * | 2020-09-04 | 2023-07-12 | Shandong Simcere Biopharmaceutical Co., Ltd. | Il-2 mutant and application thereof |
MX2023005030A (es) | 2020-10-29 | 2023-05-16 | Bristol Myers Squibb Co | Proteinas de fusion para el tratamiento de enfermedades. |
AU2022267777A1 (en) | 2021-04-30 | 2023-10-05 | Centre Hospitalier Universitaire Vaudois (Chuv) | Single vessel expansion of lymphocytes |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2024097864A1 (en) | 2022-11-02 | 2024-05-10 | Tigen Pharma Sa | Expansion of lymphocytes |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4853332A (en) | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
JP3024311B2 (ja) | 1991-10-03 | 2000-03-21 | 味の素株式会社 | Il−2受容体重鎖に結合するポリペプチド |
US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
EP1105421A2 (en) | 1998-08-21 | 2001-06-13 | Yeda Research & Development Company, Ltd. | Anti-inflammatory peptides derived from il-2 and analogues thereof |
CN100390282C (zh) * | 2001-12-04 | 2008-05-28 | 默克专利有限公司 | 具有调节的选择性的il-2融合蛋白 |
WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
JP2009542592A (ja) * | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−2媒介性免疫応答の有効性を高める組成物および方法 |
US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
DE102008023820A1 (de) * | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
-
2009
- 2009-11-27 CU CU20090203A patent/CU23734A1/es active IP Right Grant
-
2010
- 2010-11-25 AR ARP100104366A patent/AR079197A1/es active IP Right Grant
- 2010-11-26 CA CA2781173A patent/CA2781173C/en active Active
- 2010-11-26 BR BR112012012025A patent/BR112012012025B8/pt active IP Right Grant
- 2010-11-26 PE PE2012000720A patent/PE20121636A1/es not_active Application Discontinuation
- 2010-11-26 ES ES10803437.2T patent/ES2643465T3/es active Active
- 2010-11-26 WO PCT/CU2010/000005 patent/WO2011063770A2/es active Application Filing
- 2010-11-26 CN CN201080053369.9A patent/CN102665754B/zh active Active
- 2010-11-26 KR KR1020127010828A patent/KR101484590B1/ko active IP Right Grant
- 2010-11-26 AU AU2010324254A patent/AU2010324254B2/en active Active
- 2010-11-26 JP JP2012540281A patent/JP5680661B2/ja active Active
- 2010-11-26 MX MX2012006077A patent/MX2012006077A/es active IP Right Grant
- 2010-11-26 EP EP10803437.2A patent/EP2505206B1/en active Active
- 2010-11-26 SG SG2012039053A patent/SG181089A1/en unknown
- 2010-11-26 US US13/512,429 patent/US8759486B2/en active Active
- 2010-11-26 EA EA201290395A patent/EA021867B1/ru not_active IP Right Cessation
- 2010-11-26 NZ NZ599792A patent/NZ599792A/en unknown
- 2010-11-26 MY MYPI2012002130A patent/MY162324A/en unknown
-
2012
- 2012-04-17 EC ECSP12011803 patent/ECSP12011803A/es unknown
- 2012-04-20 TN TNP2012000182A patent/TN2012000182A1/en unknown
- 2012-04-23 CL CL2012001030A patent/CL2012001030A1/es unknown
- 2012-05-23 ZA ZA2012/03762A patent/ZA201203762B/en unknown
- 2012-06-06 CO CO12095471A patent/CO6501124A2/es not_active Application Discontinuation
- 2012-10-30 HK HK12110868.4A patent/HK1169961A1/xx unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112839964A (zh) * | 2018-06-07 | 2021-05-25 | 普泰公司 | 包含融合蛋白的药物组合物及其用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012012025A2 (pt) | polipeptídeo imunomodulador derivado da interleucina-2, proteína de fusão, composição farmacêutica e usos do polipeptídeo e da proteína de fusão | |
BR112017001940A2 (pt) | proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso | |
BR112016029848A2 (pt) | proteínas de fusão mic-1 e utilizações das mesmas | |
BR112013010127A2 (pt) | polipeptídeo agonista da interleucina 2, proteína de fusão, composição farmacêutica útil na terapia do câncer e enfermidades infecciosas crônicas, uso do polipeptídeo e uso da proteína de fusão | |
BR112013031268A2 (pt) | "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição". | |
BR112012029689A2 (pt) | proteína de fusão sequência de polinucleotídeo, célula hospedeira, composição farmacêutica e uso. | |
BR112016012538A2 (pt) | peptídeos citotóxicos e conjugados dos mesmos | |
CO7010783A2 (es) | Proteína naglu humana recombinante y usos de la misma | |
BR112018004536A2 (pt) | peptídeos de endereçamento à cartilagem | |
BRPI0814097A8 (pt) | Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado | |
BR112012006501A8 (pt) | Polipeptídios e usos dos mesmos | |
BRPI0510526A (pt) | formulações lìquidas estabilizadas de interferon | |
BR112017025108A2 (pt) | compostos seletivos de pyy e usos dos mesmos | |
BR112015011158A8 (pt) | triazolopirazina, seu uso e preparação farmacêutica | |
BR112015013183A2 (pt) | proteínas de fusão para uso como aperfeiçoadores imunogênicos para indução de respostas de células t específicas para antígenos | |
BR112012031183A2 (pt) | líquidos nutricionais substancialmente claros compreendendo proteína de cálcio hmb e solúvel | |
BR112016002753A2 (pt) | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos | |
BR112015022758A2 (pt) | derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia | |
CL2012001656A1 (es) | Polipéptido de somatotropina bovina que comprende uno o mas aminoácidos no naturales y que estan ligados a un polimero soluble en agua. composicion farmaceutica que comprende dichos polipeptidos. | |
CU20130012A7 (es) | Conjugado de factor estimulante de colonia de granulocito (g-csf)con polietileno glicol | |
BR112019017393A8 (pt) | Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico | |
BR112015019729A2 (pt) | composição inibidora da il-1b e uso da mesma | |
BR112013032088A2 (pt) | "polipeptídeo, composição farmacêutica e seu uso" | |
BR112015023793A2 (pt) | composições e métodos de terapias para indução de tolerância imune a substituição do fator vii em indivíduos com hemofilia a | |
BR112015022730A2 (pt) | formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/11/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/11/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |